Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Neurology

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug.
• Optimizing CBZ delivery is crucial for managing epilepsy and minimizing side effects.
• Steady-state pharmacokinetics and clinical outcomes of different CBZ formulations require investigation.

Purpose of the Study:

• To compare the pharmacokinetics, clinical efficacy, and side effects of a slow-release (SR) CBZ preparation (Neurotol Slow) versus a conventional (C) preparation (Tegretol).
• To evaluate CBZ and its metabolite carbamazepine-10,11-epoxide (CBZE) serum concentrations, seizure frequency, and adverse events in epileptic patients.

Main Methods:

• A single-blind, randomized cross-over study involving 18 adult epileptic patients on stable CBZ doses.
• Blood samples were collected over 12 hours post-dose to measure serum CBZ and CBZE concentrations using HPLC.
• Seizure counts and side effects were recorded during two 2-week treatment periods for each formulation.

Main Results:

• SR formulation resulted in significantly lower peak CBZ and CBZE concentrations and a longer time to reach peak levels.
• Serum CBZ and CBZE fluctuations were significantly reduced with SR treatment.
• Bioavailability did not differ significantly between SR and C preparations.
• Epileptic seizure frequency was lower with SR (31 seizures) compared to C (57 seizures).
• Side effects, particularly dizziness, were significantly less common with SR treatment.

Conclusions:

• Slow-release carbamazepine (SR CBZ) offers improved pharmacokinetic stability compared to conventional formulations.
• SR CBZ demonstrates enhanced clinical efficacy by reducing seizure frequency.
• The use of SR CBZ formulations can lead to a better side effect profile, improving patient tolerability and adherence.